UKI NETS 2024 Annual Conference – Sponsors


The UKI NETS 2024 Annual Conference will continue to support our NET community to promote collaborations, education and advancement of practice in the field of neuroendocrine neoplasms (NENs).


For future UKI NETS conferences 

This is the leading NET conference in UK and Ireland and we have sponsorship packages available to offer you to make the most of your conference experience.

If you are interested in any of our sponsorship and exhibition opportunities for 2024, please email [email protected]



UKI NETS would like to thank the sponsors for the UKI NETS 2023 Annual Conference


Major Meeting Partners:


We hope you joined for the Ipsen Satellite Symposium on Monday 4th December at 12:35-13:35:



The AAA Satellite symposium is approved by the UKI NETS Executive and was part of the UKI NETS Conference which continued the following day:


Society Partners:


Esteve Pharmaceuticals is an international pharmaceutical company supplying medicines to more than 7 million patients worldwide. The product portfolio comprises drugs for the treatment of serious diseases in the therapeutic areas of oncology, pain, central nervous system, ophthalmology, neurology and dermatology.
Included in our UK portfolio are Zanosar® (Streptozocin), an antineoplastic alkylating agent indicated for use in neuroendocrine tumours of pancreatic origin, and Prialt® (Ziconotide) a non-opioid intrathecal treatment for chronic pain.


We hope you visited the Esteve stand at UKI NETS 2023 in Sheffield!




ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.


Patient Support Groups

UKI NETS would like to extend its thanks to both AMEND and NCUK for their continued support of the Annual Conference.